{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T10:55:34Z","timestamp":1772189734466,"version":"3.50.1"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T00:00:00Z","timestamp":1765411200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"vor","delay-in-days":34,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2022R1A2C101043711, RS-2025-00559766"],"award-info":[{"award-number":["2022R1A2C101043711, RS-2025-00559766"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"DOI":"10.1186\/s12886-025-04560-4","type":"journal-article","created":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T15:23:20Z","timestamp":1765466600000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Selective and nonselective mineralocorticoid receptor antagonists in central serous chorioretinopathy: systematic review and meta-analysis"],"prefix":"10.1186","volume":"26","author":[{"given":"Jae Yong","family":"Park","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeonggyeong","family":"Jang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seokyung","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,12,11]]},"reference":[{"key":"4560_CR1","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/ceo.14201","volume":"51","author":"AT Fung","year":"2023","unstructured":"Fung AT, Yang Y, Kam AW. Central serous chorioretinopathy: a review. Clin Exp Ophthalmol. 2023;51:243\u201370.","journal-title":"Clin Exp Ophthalmol"},{"key":"4560_CR2","doi-asserted-by":"publisher","first-page":"100865","DOI":"10.1016\/j.preteyeres.2020.100865","volume":"79","author":"R Kaye","year":"2020","unstructured":"Kaye R, et al. Central serous chorioretinopathy: an update on risk factors, pathophysiology and imaging modalities. Prog Retin Eye Res. 2020;79:100865.","journal-title":"Prog Retin Eye Res"},{"key":"4560_CR3","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.preteyeres.2015.05.003","volume":"48","author":"A Daruich","year":"2015","unstructured":"Daruich A, et al. Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res. 2015;48:82\u2013118.","journal-title":"Prog Retin Eye Res"},{"key":"4560_CR4","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.oftal.2020.07.023","volume":"96","author":"FJ Moreno-Morillo","year":"2021","unstructured":"Moreno-Morillo FJ, et al. Update on the management of chronic central serous chorioretinopathy. Arch Soc Esp Oftalmol (Engl Ed). 2021;96:251\u201364.","journal-title":"Arch Soc Esp Oftalmol (Engl Ed)"},{"key":"4560_CR5","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1016\/j.ophtha.2018.04.021","volume":"125","author":"EHC van Dijk","year":"2018","unstructured":"van Dijk EHC, et al. Half-dose photodynamic therapy versus high-density subthreshold micropulse laser treatment in patients with chronic central serous chorioretinopathy: the PLACE trial. Ophthalmology. 2018;125:1547\u201355.","journal-title":"Ophthalmology"},{"key":"4560_CR6","doi-asserted-by":"publisher","first-page":"2672","DOI":"10.1172\/JCI61427","volume":"122","author":"M Zhao","year":"2012","unstructured":"Zhao M, et al. Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy. J Clin Invest. 2012;122:2672\u20139.","journal-title":"J Clin Invest"},{"key":"4560_CR7","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(19)32981-2","volume":"395","author":"A Lotery","year":"2020","unstructured":"Lotery A, et al. Eplerenone for chronic central serous chorioretinopathy in patients with active, previously untreated disease for more than 4 months (VICI): a randomised, double-blind, placebo-controlled trial. Lancet. 2020;395:294\u2013303.","journal-title":"Lancet"},{"key":"4560_CR8","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/s41433-020-01338-4","volume":"35","author":"J Duan","year":"2021","unstructured":"Duan J, Zhang Y, Zhang M. Efficacy and safety of the mineralocorticoid receptor antagonist treatment for central serous chorioretinopathy: a systematic review and meta-analysis. Eye (Lond). 2021;35:1102\u201310.","journal-title":"Eye (Lond)"},{"key":"4560_CR9","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s40942-022-00385-1","volume":"8","author":"CQ Felipe","year":"2022","unstructured":"Felipe CQ, et al. Mineralocorticoid receptor antagonists for chronic central serous chorioretinopathy: systematic review and meta-analyses. Int J Retina Vitreous. 2022;8:34.","journal-title":"Int J Retina Vitreous"},{"key":"4560_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1002\/jrsm.1054","volume":"3","author":"G van Valkenhoef","year":"2012","unstructured":"van Valkenhoef G, et al. Automating network meta-analysis. Res Synth Methods. 2012;3:285\u201399.","journal-title":"Res Synth Methods"},{"key":"4560_CR11","unstructured":"Higgins JPT, Chandler J, Cumpston M, Li T, Page MJ, Welch VA. Tests for funnel plot asymmetry. in: Cochrane handbook for systematic reviews of interventions version 65 (updated August 2024). Cochrane; 2024."},{"key":"4560_CR12","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1097\/IAE.0000000000000614","volume":"35","author":"E Bousquet","year":"2015","unstructured":"Bousquet E, et al. Spironolactone for nonresolving central serous chorioretinopathy: a randomized controlled crossover study. Retina. 2015;35:2505\u201315.","journal-title":"Retina"},{"key":"4560_CR13","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1007\/s10792-016-0377-2","volume":"37","author":"F Pichi","year":"2017","unstructured":"Pichi F, et al. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy. Int Ophthalmol. 2017;37:1115\u201325.","journal-title":"Int Ophthalmol"},{"key":"4560_CR14","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1111\/aos.13491","volume":"95","author":"R Schwartz","year":"2017","unstructured":"Schwartz R, et al. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study. Acta Ophthalmol. 2017;95:e610\u20138.","journal-title":"Acta Ophthalmol"},{"key":"4560_CR15","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1097\/IAE.0000000000001649","volume":"38","author":"E Rahimy","year":"2018","unstructured":"Rahimy E, et al. A randomized Double-Blind Placebo-Control pilot study of eplerenone for the treatment of central serous chorioretinopathy (Ecselsior). Retina. 2018;38:962\u20139.","journal-title":"Retina"},{"key":"4560_CR16","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1136\/bjophthalmol-2017-311096","volume":"102","author":"X Sun","year":"2018","unstructured":"Sun X, et al. Spironolactone versus observation in the treatment of acute central serous chorioretinopathy. Br J Ophthalmol. 2018;102:1060\u20135.","journal-title":"Br J Ophthalmol"},{"key":"4560_CR17","unstructured":"Masoud Reza Manaviat MMK, Miratashi AM, Shoja MR, Mahdavi M, Gohari M, Bahrami B. Golzar A., Hemmati A. Clinical trial of spironolactone effect as a treatment for acute central serous chorioretinopathy. J Biochem Tech 2019:133\u20139."},{"key":"4560_CR18","doi-asserted-by":"publisher","first-page":"3317","DOI":"10.1093\/emboj\/17.12.3317","volume":"17","author":"J Fagart","year":"1998","unstructured":"Fagart J, et al. Antagonism in the human mineralocorticoid receptor. EMBO J. 1998;17:3317\u201325.","journal-title":"EMBO J"},{"key":"4560_CR19","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jama.1973.03220280028007","volume":"225","author":"DJ Greenblatt","year":"1973","unstructured":"Greenblatt DJ, Koch-Weser J. Adverse reactions to spironolactone. a report from the Boston collaborative drug surveillance program. JAMA. 1973;225:40\u20133.","journal-title":"JAMA"},{"key":"4560_CR20","doi-asserted-by":"publisher","first-page":"709","DOI":"10.2174\/1389557054553811","volume":"5","author":"X Hu","year":"2005","unstructured":"Hu X, et al. Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone. Mini Rev Med Chem. 2005;5:709\u201318.","journal-title":"Mini Rev Med Chem"},{"key":"4560_CR21","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S0022-3565(25)22580-0","volume":"240","author":"M de Gasparo","year":"1987","unstructured":"de Gasparo M, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther. 1987;240:650\u20136.","journal-title":"J Pharmacol Exp Ther"},{"key":"4560_CR22","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1097\/IAE.0b013e3181be0a83","volume":"29","author":"Y Imamura","year":"2009","unstructured":"Imamura Y, et al. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina. 2009;29:1469\u201373.","journal-title":"Retina"},{"key":"4560_CR23","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","volume":"27","author":"J Yang","year":"2016","unstructured":"Yang J, Young MJ. Mineralocorticoid receptor antagonists-pharmacodynamics and Pharmacokinetic differences. Curr Opin Pharmacol. 2016;27:78\u201385.","journal-title":"Curr Opin Pharmacol"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12886-025-04560-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-025-04560-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T10:55:49Z","timestamp":1768388149000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12886-025-04560-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,11]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4560"],"URL":"https:\/\/doi.org\/10.1186\/s12886-025-04560-4","relation":{},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,11]]},"assertion":[{"value":"1 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"None.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Meeting presentation"}}],"article-number":"26"}}